{'52WeekChange': -0.4102564,
 'SandP52WeekChange': None,
 'address1': '1 Great Valley Parkway',
 'address2': 'Suite 30',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.84,
 'askSize': 800,
 'averageDailyVolume10Day': 822000,
 'averageVolume': 804914,
 'averageVolume10days': 822000,
 'beta': None,
 'beta3Year': None,
 'bid': 4.7,
 'bidSize': 1000,
 'bookValue': 1.858,
 'category': None,
 'circulatingSupply': None,
 'city': 'Malvern',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.12,
 'dayLow': 4.65,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.981,
 'enterpriseToRevenue': 45.366,
 'enterpriseValue': 92002288,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '610 981 6520',
 'fiftyDayAverage': 4.8602858,
 'fiftyTwoWeekHigh': 9.82,
 'fiftyTwoWeekLow': 2.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14850155,
 'forwardEps': -2.36,
 'forwardPE': -1.9830508,
 'fromCurrency': None,
 'fullTimeEmployees': 40,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.1428,
 'heldPercentInstitutions': 0.77911,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/phasebio.com',
 'longBusinessSummary': 'PhaseBio Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of novel for cardiopulmonary '
                        'diseases. Its lead product candidate is PB2452, a '
                        'reversal agent for the antiplatelet drug ticagrelor '
                        'that is in Phase III clinical trial for patients '
                        'experiencing uncontrolled bleeding events or in '
                        'patients requiring urgent or emergency surgery. The '
                        'company is also developing PB1046, a vasoactive '
                        'intestinal peptide analogue that is in Phase IIb '
                        'clinical trial for the treatment of pulmonary '
                        'arterial hypertension; and PB6440, an oral agent for '
                        'the treatment of resistant hypertension. The company '
                        'has a co-development agreement with SFJ '
                        'Pharmaceuticals X, Ltd. to develop PB2452, a reversal '
                        'agent for the antiplatelet drug ticagrelor. PhaseBio '
                        'Pharmaceuticals, Inc. was founded in 2002 and is '
                        'based in Malvern, Pennsylvania.',
 'longName': 'PhaseBio Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 134695072,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_3564616',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -46859000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.09,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '610 981 6500',
 'previousClose': 5.06,
 'priceHint': 4,
 'priceToBook': 2.5188372,
 'priceToSalesTrailing12Months': 66.41769,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.12,
 'regularMarketDayLow': 4.65,
 'regularMarketOpen': 5.09,
 'regularMarketPreviousClose': 5.06,
 'regularMarketPrice': 5.09,
 'regularMarketVolume': 368015,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 28781000,
 'sharesPercentSharesOut': 0.1089,
 'sharesShort': 3134958,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1980512,
 'shortName': 'PhaseBio Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.25010002,
 'shortRatio': 7.28,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'PHAS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.641,
 'twoHundredDayAverage': 4.517554,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '71821add-433e-378b-90a2-770129db561a',
 'volume': 368015,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://phasebio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19355'}